Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dallah Healthcare CoSAU:4004 +2.17%90 5-Year Yield-on-Cost % is 3.12 as of Aug. 23, 2026, which is 20% above its 10-year median of 2.61. GuruFocus rates SAU:4004 with a GF Score™ of 90/100 and a GF Value™ of ﷼196.61 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 278 Healthcare Providers & Services companies, Dallah Healthcare Co ranks better than 52.88% on this metric.
Dallah Healthcare Co's yield on cost for the quarter that ended in Jun. 2026 was 3.12.
The historical rank and industry rank for Dallah Healthcare Co's 5-Year Yield-on-Cost % or its related term are showing as below:
SAU:4004'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.26 Med: 2.61 Max: 14.94
Current: 3.12
During the past 13 years, Dallah Healthcare Co's highest Yield on Cost was 14.94. The lowest was 1.26. And the median was 2.61.
SAU:4004's 5-Year Yield-on-Cost % is ranked better than 52.88% of 278
companies
in the Healthcare Providers & Services industry
Industry Median: 2.965
vs SAU:4004: 3.12
Dallah Healthcare Co (SAU:4004) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Dallah Healthcare Co 5-Year Yield-on-Cost % Related Terms
SAU:4004 vs HCA, THC, DVA: 5-Year Yield-on-Cost % Comparison
For the Medical Care Facilities subindustry, Dallah Healthcare Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dallah Healthcare Co 5-Year Yield-on-Cost % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Dallah Healthcare Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Dallah Healthcare Co's 5-Year Yield-on-Cost % falls into.
Dallah Healthcare Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Dallah Healthcare Co (SAU:4004) has a 5-Year Yield-on-Cost % of 3.12 as of Aug. 23, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Dallah Healthcare Co and its competitors. This is 20% above median its historical median of 2.61. Over the past decade, Dallah Healthcare Co's 5-Year Yield-on-Cost % has ranged from 1.26 to 14.94. According to the industry distribution chart, Dallah Healthcare Co ranks #131 out of 278 companies in the Healthcare Providers & Services industry, placing it in the top 47.1%.
Is Dallah Healthcare Co's 5-Year Yield-on-Cost % too high?
Dallah Healthcare Co's current 5-Year Yield-on-Cost % of 3.12 is 20% above median its 10-year median of 2.61. Over the past 10 years, this metric has ranged from a low of 1.26 to a high of 14.94. The Healthcare Providers & Services industry median 5-Year Yield-on-Cost % is 2.97. Dallah Healthcare Co's value of 3.12 is 5.2% above this industry median. Based on the distribution chart, Dallah Healthcare Co ranks #131 out of 278 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Dallah Healthcare Co has a GF Score™ of 90/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dallah Healthcare Co's 5-Year Yield-on-Cost % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Dallah Healthcare Co ranks #131 out of 278 companies for 5-Year Yield-on-Cost %. This puts Dallah Healthcare Co in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.97. Dallah Healthcare Co's value of 3.12 is 5.2% above this benchmark. Historically, Dallah Healthcare Co's own 5-Year Yield-on-Cost % has ranged from 1.26 to 14.94 over the past decade. While the company's 10-year median is 2.61 vs. the industry median of 2.97, Dallah Healthcare Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Healthcare Providers & Services company?
The median 5-Year Yield-on-Cost % among Healthcare Providers & Services companies is 2.97, based on 278 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dallah Healthcare Co's current 5-Year Yield-on-Cost % of 3.12 is 5.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Dallah Healthcare Co and its competitors. For the Healthcare Providers & Services industry, the median 5-Year Yield-on-Cost % is 2.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dallah Healthcare Co's current 5-Year Yield-on-Cost % is 3.12, which is 20% above median its own 10-year median of 2.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dallah Healthcare Co stock overvalued right now?
Based on GuruFocus' analysis, Dallah Healthcare Co (SAU:4004) is currently considered Significantly Undervalued. The stock's GF Value™ is ﷼196.61, compared to a current price of ﷼101.20 — trading 48.5% below its estimated fair value. The current 5-Year Yield-on-Cost % is 3.12, which is 20% above median its 10-year median of 2.61 and 5.2% above the Healthcare Providers & Services industry median of 2.97. Dallah Healthcare Co's overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Dallah Healthcare Co (SAU:4004), the current 5-Year Yield-on-Cost % is 3.12 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dallah Healthcare Co (SAU:4004) Overvalued in 2026?
Based on GuruFocus' analysis, Dallah Healthcare Co stock appears to be undervalued.
The current stock price of ﷼101.20 is trading 48.5% below its estimated GF Value™ of ﷼196.61.
GuruFocus considers Dallah Healthcare Co to be Significantly Undervalued.
Key valuation signals for SAU:4004:
5-Year Yield-on-Cost %: 3.12 (20% above median its 10-year median of 2.61)
GF Value™: ﷼196.61 vs. price of ﷼101.20 (48.5% below fair value)
Industry Position: 5.2% above the Healthcare Providers & Services median (#131 of 278)
No single metric tells the full story. See the SAU:4004 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dallah Healthcare Co provides and operates healthcare programs and utilities in the Kingdom of Saudi Arabia. The objectives of the company include operating, managing, and maintaining the healthcare entities, wholesale medicines, and retail of medical and surgical equipment, prosthetics, and devices for the disabled, hospital equipment, and manufacturing medicines, pharmaceuticals, herbals, health, cosmetics, detergents, disinfectants, and packaging in the Kingdom of Saudi Arabia. The reportable segments of the company are Medical Facilities and Pharmacies, and Distribution of Pharmaceutical Products. The company generates the majority of its revenue from the Medical Facilities and Pharmacies segment.
90GF Score
Get the complete analysis for SAU:4004
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:4004 has been successfully added to your 
